学龄儿童接种第 4 剂和第 5 剂脊髓灰质炎灭活疫苗后的免疫持久性。

IF 10.9 1区 医学 Q1 INFECTIOUS DISEASES Clinical Microbiology and Infection Pub Date : 2024-10-12 DOI:10.1016/j.cmi.2024.10.007
Kathy Leung, Chrissy W K Pang, Tiffany H K Lo, Juan C Vargas-Zambrano, Céline Petit, Tommy T Y Lam, Eric H Y Lau, Joseph T Wu
{"title":"学龄儿童接种第 4 剂和第 5 剂脊髓灰质炎灭活疫苗后的免疫持久性。","authors":"Kathy Leung, Chrissy W K Pang, Tiffany H K Lo, Juan C Vargas-Zambrano, Céline Petit, Tommy T Y Lam, Eric H Y Lau, Joseph T Wu","doi":"10.1016/j.cmi.2024.10.007","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to assess the long-term persistence of neutralizing antibodies (nAb) titres and seroprotection proportions after the fourth and fifth doses of inactivated polio vaccine (IPV).</p><p><strong>Methods: </strong>Serum samples from 299 children in Hong Kong were collected and used to estimate the persistence of nAb titres and seroprotection proportions by neutralisation test.</p><p><strong>Results: </strong>The mean nAb titres against poliovirus types 1, 2, and 3 (PV1, PV2, and PV3) 1 month after receiving the fourth dose of IPV at 19 months of age were 2068 (95% credible interval, 1517-2864); 4705 (3439-6436); and 2758 (1894-4086); respectively, but declined substantially in 4 years to 268 (222-325), 751 (630-900), and 411 (323-521), respectively. Administration of the fifth dose of IPV restored nAb titres among children aged 6 to 7 years, and the decline in nAb titres was slightly slower with the estimated mean titres of 355 (272-462), 538 (427-681), and 548 (378-786) against PV1, PV2, and PV3 at 4 years post the fifth dose. We estimated that the proportion of children who were seroprotected against PV1, PV2, and PV3 would drop below 90%: (i) 8.2, 10.8, and 8.7 years after the fourth dose; and (ii) 11.6, 11.2, and 11.0 years after the fifth dose.</p><p><strong>Discussion: </strong>The results revealed the immuno-persistence after the fourth and fifth doses of IPV and highlighted the importance of completing immunization series to ensure high vaccination coverage, particularly among children in the developing countries affected by the COVID-19 pandemic.</p>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":null,"pages":null},"PeriodicalIF":10.9000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immuno-persistence after the fourth and fifth doses of inactivated polio vaccines in school-aged children.\",\"authors\":\"Kathy Leung, Chrissy W K Pang, Tiffany H K Lo, Juan C Vargas-Zambrano, Céline Petit, Tommy T Y Lam, Eric H Y Lau, Joseph T Wu\",\"doi\":\"10.1016/j.cmi.2024.10.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>This study aimed to assess the long-term persistence of neutralizing antibodies (nAb) titres and seroprotection proportions after the fourth and fifth doses of inactivated polio vaccine (IPV).</p><p><strong>Methods: </strong>Serum samples from 299 children in Hong Kong were collected and used to estimate the persistence of nAb titres and seroprotection proportions by neutralisation test.</p><p><strong>Results: </strong>The mean nAb titres against poliovirus types 1, 2, and 3 (PV1, PV2, and PV3) 1 month after receiving the fourth dose of IPV at 19 months of age were 2068 (95% credible interval, 1517-2864); 4705 (3439-6436); and 2758 (1894-4086); respectively, but declined substantially in 4 years to 268 (222-325), 751 (630-900), and 411 (323-521), respectively. Administration of the fifth dose of IPV restored nAb titres among children aged 6 to 7 years, and the decline in nAb titres was slightly slower with the estimated mean titres of 355 (272-462), 538 (427-681), and 548 (378-786) against PV1, PV2, and PV3 at 4 years post the fifth dose. We estimated that the proportion of children who were seroprotected against PV1, PV2, and PV3 would drop below 90%: (i) 8.2, 10.8, and 8.7 years after the fourth dose; and (ii) 11.6, 11.2, and 11.0 years after the fifth dose.</p><p><strong>Discussion: </strong>The results revealed the immuno-persistence after the fourth and fifth doses of IPV and highlighted the importance of completing immunization series to ensure high vaccination coverage, particularly among children in the developing countries affected by the COVID-19 pandemic.</p>\",\"PeriodicalId\":10444,\"journal\":{\"name\":\"Clinical Microbiology and Infection\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":10.9000,\"publicationDate\":\"2024-10-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Microbiology and Infection\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cmi.2024.10.007\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Microbiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cmi.2024.10.007","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

研究目的本研究旨在评估接种第四剂和第五剂脊髓灰质炎灭活疫苗(IPV)后,中和抗体滴度(nAb)的长期持续性和血清保护比例:方法:收集香港 299 名儿童的血清样本,通过中和试验估算 nAb 滴度的持续性和血清保护比例:结果:在19个月大时接受第4剂IPV一个月后,针对1、2和3型脊髓灰质炎病毒(PV1、PV2和PV3)的nAb滴度平均值为2,068(95%可信区间:1,517 - 2,86):但在 4 年后大幅下降,分别为 268(222 - 325)、751(630 - 900)和 411(323 - 521)。第 5 次注射 IPV 后,6-7 岁儿童的 nAb 滴度有所恢复,而 nAb 滴度的下降速度稍慢,估计在第 5 次注射后的 4 年中,针对 PV1、PV2 和 PV3 的平均滴度分别为 355(272 - 462)、538(427 - 681)和 548(378 - 786)。我们估计,在下列情况下,对 PV1、PV2 和 PV3 具有血清保护作用的儿童比例将降至 90% 以下:(i) 第 4 次接种后的 8.2、10.8 和 8.7 年;以及 (ii) 第 5 次接种后的 11.6、11.2 和 11.0 年:研究结果表明,在接种第 4 剂和第 5 剂 IPV 后,免疫力会持续存在,并强调了完成系列免疫接种以确保高疫苗接种覆盖率的重要性,尤其是在受 COVID-19 大流行影响的发展中国家的儿童中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Immuno-persistence after the fourth and fifth doses of inactivated polio vaccines in school-aged children.

Objectives: This study aimed to assess the long-term persistence of neutralizing antibodies (nAb) titres and seroprotection proportions after the fourth and fifth doses of inactivated polio vaccine (IPV).

Methods: Serum samples from 299 children in Hong Kong were collected and used to estimate the persistence of nAb titres and seroprotection proportions by neutralisation test.

Results: The mean nAb titres against poliovirus types 1, 2, and 3 (PV1, PV2, and PV3) 1 month after receiving the fourth dose of IPV at 19 months of age were 2068 (95% credible interval, 1517-2864); 4705 (3439-6436); and 2758 (1894-4086); respectively, but declined substantially in 4 years to 268 (222-325), 751 (630-900), and 411 (323-521), respectively. Administration of the fifth dose of IPV restored nAb titres among children aged 6 to 7 years, and the decline in nAb titres was slightly slower with the estimated mean titres of 355 (272-462), 538 (427-681), and 548 (378-786) against PV1, PV2, and PV3 at 4 years post the fifth dose. We estimated that the proportion of children who were seroprotected against PV1, PV2, and PV3 would drop below 90%: (i) 8.2, 10.8, and 8.7 years after the fourth dose; and (ii) 11.6, 11.2, and 11.0 years after the fifth dose.

Discussion: The results revealed the immuno-persistence after the fourth and fifth doses of IPV and highlighted the importance of completing immunization series to ensure high vaccination coverage, particularly among children in the developing countries affected by the COVID-19 pandemic.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
25.30
自引率
2.10%
发文量
441
审稿时长
2-4 weeks
期刊介绍: Clinical Microbiology and Infection (CMI) is a monthly journal published by the European Society of Clinical Microbiology and Infectious Diseases. It focuses on peer-reviewed papers covering basic and applied research in microbiology, infectious diseases, virology, parasitology, immunology, and epidemiology as they relate to therapy and diagnostics.
期刊最新文献
Real-world effectiveness of nirmatrelvir-ritonavir and molnupiravir in non-hospitalised adults with Covid-19: a population-based, retrospective cohort study cohort study. A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intraabdominal infections. Re: 'Heightened incidence of adverse events associated with a live attenuated varicella vaccine strain that lacks critical genetic polymorphisms in ORF62' by Kang et al. Epidemiology of human metapneumovirus among children with severe or very severe pneumonia in high pneumonia burden settings: the PERCH study experience. 'Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort study' - Author's reply.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1